Rep. Robert Bresnahan, Jr. Buys Centene Co. (NYSE:CNC) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Centene Co. NYSE: CNC. In a filing disclosed on May 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Centene stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Occidental Petroleum NYSE: OXY on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 4/8/2025.
• Sold $1,001 - $15,000 in shares of QUALCOMM NASDAQ: QCOM on 4/8/2025.

Centene Stock Up 0.6 %

CNC stock opened at $62.82 on Friday. The firm's fifty day moving average is $60.53 and its 200 day moving average is $60.50. The firm has a market cap of $31.26 billion, a PE ratio of 10.07, a P/E/G ratio of 0.80 and a beta of 0.48. Centene Co. has a one year low of $55.03 and a one year high of $80.59. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.10 and a current ratio of 1.11.

Centene (NYSE:CNC - Get Free Report) last announced its earnings results on Friday, April 25th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.52 by $0.38. Centene had a return on equity of 13.85% and a net margin of 2.03%. The firm had revenue of $46.62 billion for the quarter, compared to analyst estimates of $43.16 billion. During the same quarter last year, the firm posted $2.26 EPS. The business's revenue was up 15.4% on a year-over-year basis. On average, research analysts forecast that Centene Co. will post 6.86 EPS for the current year.

Hedge Funds Weigh In On Centene

Institutional investors and hedge funds have recently modified their holdings of the company. Osborne Partners Capital Management LLC boosted its position in shares of Centene by 5.0% during the 4th quarter. Osborne Partners Capital Management LLC now owns 221,156 shares of the company's stock worth $13,398,000 after acquiring an additional 10,515 shares in the last quarter. Perpetual Ltd increased its stake in Centene by 68.4% in the fourth quarter. Perpetual Ltd now owns 36,126 shares of the company's stock valued at $2,189,000 after purchasing an additional 14,671 shares during the last quarter. Polianta Ltd raised its holdings in Centene by 41.7% during the fourth quarter. Polianta Ltd now owns 22,100 shares of the company's stock worth $1,338,000 after purchasing an additional 6,500 shares in the last quarter. KBC Group NV lifted its position in shares of Centene by 27.3% during the 4th quarter. KBC Group NV now owns 1,602,533 shares of the company's stock worth $97,082,000 after buying an additional 343,559 shares during the last quarter. Finally, Washington Capital Management Inc. raised its stake in Centene by 40.9% during the 4th quarter. Washington Capital Management Inc. now owns 19,130 shares of the company's stock worth $1,159,000 after acquiring an additional 5,550 shares in the last quarter. Institutional investors and hedge funds own 93.63% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on CNC shares. StockNews.com cut shares of Centene from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 28th. Jefferies Financial Group lowered their target price on Centene from $64.00 to $61.00 and set a "hold" rating on the stock in a report on Tuesday, April 29th. Argus cut Centene from a "buy" rating to a "hold" rating in a report on Thursday, February 6th. Wells Fargo & Company cut their target price on Centene from $76.00 to $72.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Finally, Guggenheim reissued a "neutral" rating on shares of Centene in a research report on Tuesday, April 29th. Seven equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $79.77.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Centene

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.